Heterogeneity within AML with CEBPA mutations; Only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

British Journal of Cancer

Volumn 100, Issue 8, 2009, Pages 1343-1346

  Pabst, T ^a   Eyholzer, M ^a   Fos, J ^a   Mueller, B U ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

AML; CEBPA; Mutations; Prognosis; Riskassessment

Indexed keywords

ANTINEOPLASTIC AGENT; CCAAT ENHANCER BINDING PROTEIN ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; WILD TYPE;

BONE MARROW; CCAAT-ENHANCER-BINDING PROTEINS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENES, REPORTER; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; LUCIFERASES; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 64949122396     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604977     Document Type: Article

References (15)

1. Bienz M, Ludwig M, Oppliger E, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11: 1416-1425
2. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633
3. Gaidzik V, Dohner K (2008) Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 35: 346-355
4. Helbling D, Mueller BU, Timchenko NA, Hagemeijer A, Jotterand M, Meyer-Monard S, Lister A, Rowley JD, Huegli B, Fey MF, Pabst T (2004) The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci USA 101: 13312-13317
5. Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, Jotterand M, Meyer-Monard S, Fey MF, Pabst T (2005) CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 106: 1369-1375
6. Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD (2008) Prognostic significance of, and gene and micro RNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a cancer and leukemia group B study. J Clin Oncol 26: 5078-5087
7. Nerlov C (2004) C/EBP alpha mutations in acute myeloid leukaemias. Nat Rev Cancer 4: 394-400
8. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG (2001a) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27: 263-270
9. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG (2001b) AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7: 444-451
10. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG (1998) CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18: 4301-4314
11. Radomska HS, Basseres DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y, Sternberg DW, Lokker N, Giese NA, Bohlander SK, Schnittger S, Delmotte MH, Davis RJ, Small D, Hiddemann W, Gilliland DG, Tenen DG (2006) Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 203: 371-381
12. Rosenbauer F, Tenen DG (2007) Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 7: 105-117
13. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H (2008) Mutations and treatment outcome in cyto-genetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918
14. Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R (2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109: 389-390
15. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94: 569-574